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Abstract
Aims
Non-Coeliac Gluten Sensitivity (NCGS) is poorly understood, particularly in terms of its neu-
rological outcomes. We initially conducted a prospective postal survey to investigate its neu-
rological presentation and symptom course. Results from this then motivated a follow-up
pilot study utilising brain MRI to characterise potential diagnostic biomarkers for future
research.
Methods
Patients with NCGS were recruited from a specialist centre and completed a prospective postal
questionnaire (N = 125). This summarised symptoms experienced, their severity and their
course. Onset time was compared by Chi-squared analysis to data from the same centre con-
cerning coeliac disease patients (N = 224). Five respondents on a strict gluten-free diet who
self-reported brain fog then attended a pilot study, completing MR brain imaging/questionnaires
before/after a gluten challenge. “Baseline” data were assessed for abnormalities, while symp-
tom severity and cerebral blood flow (CBF) were compared before/after challenge.
Results
Survey participants were aged 47 (85% female). Prevalence of neurological symptoms
were: headaches (51%), brain fog (48%), balance issues (31%), tingling (19%). Median
symptom resolution time was 48 hours, while onset was 90 minutes; onset pattern was not
significantly different compared to CD patients (p = 0.322). Extra-intestinal symptoms wors-
ened by 37%(28) during a typical reaction. Predominantly non-statistical observations from
the brain imaging study are discussed.
Conclusions
Neurological symptoms in NCGS are common, and onset time is comparable to that in CD.
Brain imaging may be a useful future means of investigating physiological injury and
responses to gluten in further study.
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Introduction
Non-coeliac gluten sensitivity (NCGS) describes people who self-report gastrointestinal symp-
toms after ingesting gluten, but do not have coeliac disease (CD) or wheat allergy [1]. NCGS is
thought to affect approximately 10% of the general population [2]. Symptoms resolve on a glu-
ten-free diet (GFD) and are similar to what is seen in CD, largely revolving around gastrointes-
tinal discomforts but also with extra-intestinal involvement. Neurological symptoms such as
headache and brain fog have been reported [2, 3].
The physiological basis of NCGS is poorly understood. People who follow a GFD for “life-
style” reasons [4, 5], and the overlap between NCGS and conditions such as IBS adds heteroge-
neity into the population [5–7]. However, studies have shown evidence of a physiological
reaction in patients [8–10], including raised levels of gluten-specific, gliadin antibodies (AGA)
[11]. Notably, a meta-analysis of randomised, placebo controlled trials [12] has shown an over-
all effect in favour of NCGS subjects experiencing symptoms when trials are restricted to those
which follow the “Salerno” expert criteria [13]. As current tools such as AGA tests do not per-
form well diagnostically [14], the Salerno group have also highlighted the need for studies to
identify other biomarkers for the condition.
To date, no study has directly focused on the aforementioned neurological symptoms in
“classic” (i.e. gastrointestinal) NCGS. The physiological basis of these symptoms may offer
new brain-based biomarkers, which would complement others focused on the gut and
immune response [13] for use in future trials. Potential candidates for these may be similar to
those already reported for CD which would include pathologies such as white matter lesions
[15] or altered cerebellar biochemistry [16], as well as “dynamic” variables such as cerebral
blood flow (CBF) [17] which may change by measurable degrees alongside symptom onset fol-
lowing a gluten challenge. Brain imaging has never been conducted on classic NCGS patients,
meaning pilot data would be very valuable.
Deeper investigation of other, broader NCGS features would also assist planning of future
trials. These include the prevalence of NCGS patients who self-report feeling at least 30%
worse after eating gluten, which is a one of the Salerno criteria and may therefore be an impor-
tant inclusion criteria. Symptom course is also poorly understood, with no available studies
reporting symptom onset time in adults within a period of less than 6 hours [3, 18]. These
details are important for the planning of experiments which may seek to measure a physiologi-
cal response following a gluten challenge, as onset times of one hour compared to six hours
carry very different implications for the feasibility of study visit plans.
Aims
We conducted a postal questionnaire of patients who have been diagnosed with NCGS follow-
ing referral to a specialist CD clinic, characterising overall symptom course, as well as the fre-
quency of neurological symptoms and their severity. This motivated follow-up pilot study on a
group of respondents to perform the first brain imaging experiment of NCGS.
Methods
Participants
Participants comprised patients who had previously been referred to a specialist gastroenterol-
ogy celiac clinic in Sheffield (UK) after self-reporting gluten sensitivity. All patients had gluten
sensitivity but had completed clinical investigations which ruled out CD (HLA-DQ2 & DQ8
tested, gluten challenge of 10g gluten daily for 6 weeks followed by a gastroscopy, duodenal
biopsy and antibody testing for TTG, EMA and IgA level). Patients were initially contacted by
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letter in February of 2018, inviting them to complete an accompanying survey. A pool of 221
patients were approached, and 125 returned completed questionnaires. Ethics for the ques-
tionnaire were approved via the North Sheffield REC.
Questionnaire
The current analyses focus on a subset of responses given to a larger postal questionnaire,
which overall took ten minutes to complete. Regarding the present study, demographic infor-
mation and answers to a series of bespoke questions were collected. These assessed what symp-
toms are experienced during a typical gluten reaction; the multiple-choice symptom options
were based on those given in the Reactions Experienced After Consuming Gluten (REAC-G)
[19] tool, although this was modified to include additional neurological outcomes as available
options (brain fog, feeling off-balance & tingling sensations). The REAC-G was also replicated
to ask about symptom onset and resolution time (responses to these questions were given as a
“free text” entry). Finally, visual analogue scales based on Salerno criteria guidance [13]
assessed symptom severity. To consider the known variation in presentation experienced by
NCGS patients, this was done twice to separately estimate the magnitude of overall intestinal /
extra-intestinal symptoms.
Overview of available serological information and control reference data
As part of their initial clinical investigations many NCGS patients had also been tested for glia-
din antibodies (AGA). The kit used for this differed based on the date of their care, as the local
hospital trust switched the ELISA assay to “Phadia 2500” in 2015 [20]. The study team have
collected data of AGA incidence in healthy volunteers using the same method for the purposes
of kit calibration; at the time of writing this has been completed in 96 people without any
known gluten sensitivity. The AGA positivity rate (IgA or IgG) in NCGS survey respondents
who were assessed with the current kit was ascertained for comparison to the rate in these
healthy volunteers.
Pilot MRI study
Respondents who had indicated on the survey that they were on a strict gluten-free diet, that
brain fog was a symptom they experienced and that their symptoms usually take less than 2
hours to begin following gluten ingestion were invited to the pilot study. Further criteria were
then applied when discussing joining; no history of diagnosed neurological or psychiatric con-
ditions (except for depression), no history of drug/alcohol misuse, not currently taking any
psychoactive medication, not currently participating in any other research studies and no con-
traindications to MRI scanning. Twenty-nine potential subjects were approached before 5
were recruited. Ethics for the pilot scanning study was approved by the Yorkshire and the
Humber REC.
The overall design of the imaging experiment involved a baseline scan, followed by a gluten
challenge, followed by a second brain MRI scan. Immediately before each scan, visual analogue
scales measuring anxiety, depression, headache, “clear-headedness” and overall healthstate
symptoms were given. The Hospital Anxiety and Depression scale (HADS [21]) was also com-
pleted once in the pre-challenge testing session, also before that scan.
Gluten challenge
Subjects chose their own gluten challenge, which they ate under the supervision of a study
team member. All participants chose to eat a single sandwich which was either bought from a
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store, or made at home using store-bought bread. Though there will be variability within this,
it has been previously estimated that two slices of wheat bread contain approximately 3g of glu-
ten [22].
Imaging and clinical reporting of results
Imaging was performed on a 3T Philips Ingenia scanner. Sequences were chosen that are effec-
tive at investigating for specific phenomena which have been previously reported in CD. These
included T1-weighted (T1), FLAIR, Magnetic Resonance Spectroscopy (MRS) of the vermis (a
grey matter region of the cerebellum) and Arterial Spin Labelling (ASL) scans.
Assessment of FLAIR and MRS scans were intended to replicate types of routine clinical
investigation. The FLAIR scans were assessed by a consultant neuroradiologist for white mat-
ter lesions of a clinically suspicious level (with respect to the patient age). The N-Acetylaspar-
tate/Creatine (NAA/Cr) ratio was determined from the MRS scan and compared to cut-off
points to determine abnormal levels, also replicating local clinical protocols. These cut-offs are
locally calibrated with respect to healthy control data previously collected from the same scan-
ner, and are set as 2 standard deviations below that control mean. ASL data were used to calcu-
late grey matter CBF before / after gluten challenge.
Full information about image acquisitions and processing are available in the S2 File.
Data analysis
All analyses were conducted using SPSS.
Postal survey. For the postal survey, variables concerning symptom-type frequency,
symptom onset/resolution time and symptom severity were summarised. Symptom onset time
was converted to categorical increments which matched those in a previously reported study
from the same centre which focused on symptom onset time in a population of biopsy-proven
CD patients (N = 224; [23]); the pattern of onset was then compared with this CD data by Chi-
squared analysis. AGA positivity in respondents who were tested with the current kit was com-
pared by Chi-squared testing to the rate of positivity in healthy volunteer data. Testing was
conducted with the maximum amount of survey data available per-analysis.
Imaging study. The imaging study is included and intended as a pilot analysis for “obser-
vational” interest in providing the first data of this kind. This data for the most part was not
subjected to statistical testing; results fromMRI scanning were summarised in terms of evi-
dence of white matter disease and abnormal MRS results according to clinical protocols, while
participants who scored above conventional cut-offs to indicate either depression or anxiety
on the HADS scale were also identified. In terms of the gluten intervention, percentage change
in grey matter CBF between the pre- and post-gluten acquisitions was calculated, and change
in symptom scores as measured by visual analogue scales was compared by paired t-test.
Results
Postal survey
The mean age of the 125 respondents was 47 years (range: 18–78, SD = 14) with 84.8% being
female. Of the respondents, 39 had been tested for AGA using the current assay with 7 being
found positive (17.9%). Data collected in 96 healthy volunteers as part of calibration work for
the same kit has overall shown 12 to be positive (12.5%). This is not significantly different by
X2 comparison (p = 0.409).
The most common intestinal symptom was abdominal discomfort (78.8% of subjects),
while the most common extra-intestinal one was fatigue (71.2%). Of note, headache was
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reported in 50.8% of subjects, brain fog in 48.3%, feeling off-balance in 31.4% and tingling sen-
sations in 18.6%. All responses are shown in Fig 1.
The mean(SD) overall severity of symptoms while suffering a reaction (where 0% represents
no discomfort and 100% represents maximum discomfort according to the visual analogue
scale responses) was 74.1%(21.9) for intestinal symptoms and 70.3%(27.6) for extra-intestinal
symptoms. This represented a mean increase in severity of discomfort (when compared to the
gluten-free baseline) of 45.3%(24.4) for intestinal symptoms and 36.5%(27.5) for extra-intesti-
nal symptoms. The fraction of participants who estimated they felt more than 30% worse dur-
ing a reaction was 75.9% for intestinal symptoms and 61.1% for extra-intestinal symptoms.
Overall, the fraction of participants for who reported at least one of these phenotypes to
worsen by over 30% was 83.3%.
Median symptom onset time was 90 minutes; 44.9% of participants reported that symptoms
occurred in an hour or less, while 87.0% reported them to start within 12 hours. Median symp-
tom resolution was 48 hours, with 78.0% of participants reporting that symptoms resolved
within a week. Chi-squared analysis comparing symptom onset time to previously collected/
reported data from CD patients (N = 167) showed no significant difference (p = 0.322, see
Fig 2).
Fig 1. A bar chart showing the percentage prevalence of different symptoms in gluten reactions from the postal survey. “Canker sores” is synonymous with mouth
ulcers, i.e. oral aphthae.
https://doi.org/10.1371/journal.pone.0238283.g001
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Pilot imaging study
Demographic information for the five subjects who attended this pilot study are shown in
Table 1, alongside “baseline” observations variables with respect to their clinical normality.
Reports based on their FLAIR images indicated three had suspicious levels of white matter
lesions, while NAA/Cr values of the vermis were found to fall below the cut-off in two of these
subjects. Using conventional cut-offs, HADS scores indicated one subject to be “borderline”
for both depression and anxiety (i.e. scored between 8–10), and another subject met full crite-
ria for anxiety (i.e. score>10). Each of these subjects had also exhibited either abnormal white
matter of NAA/Cr findings.
Table 2 shows results pertaining to the gluten challenge. Symptom scores before / after glu-
ten (where a higher score always indicates a worse outcome) were not significantly different
for feelings of anxiety, depression or overall healthstate. These scores also did not show a con-
sistent direction of change. However, headache (before; 7.91±5.73, after; 29.79±17.09, p =
0.027) and brain fog (before; 19.58±30.16, after; 50.83±32.22, p = 0.042) scores significantly
and consistently worsened across all subjects. ASL imaging to explore any changes in grey mat-
ter CBF due to gluten did not show a consistent pattern of change; grey matter perfusion values
for four of the five subjects variably rose or fell by magnitudes of approximately 10% or less.
However, of potential note CBF for the remaining subject was recorded as being 68.4% higher
after eating gluten.
Fig 2. Histogram showing the overall pattern of symptom onset time after eating gluten, compared between the
current NCGS postal survey population and previously-collected data from CD patients.
https://doi.org/10.1371/journal.pone.0238283.g002
Table 1. Demographic and baseline characteristics of the subjects who attended the imaging pilot study. The NAA/Cr cut-off for abnormal readings in�0.95. HADS
cut-offs are according to convention where<8 is a “non-case”, 8–10 is a “doubtful case” and>10 is a “case”.
Subject Age Sex White Matter Report (bold if
abnormal)
NAA/Cr result (bold if
abnormal)
HADS—Depression score (bold if
abnormal)
HADS—Anxiety score (bold if
abnormal)
1 33 F Abnormal 0.97 9 9
2 37 F Normal 1.00 3 4
3 68 M Abnormal 0.95 2 6
4 32 F Abnormal 0.87 4 11
5 33 F Normal 1.05 0 1
https://doi.org/10.1371/journal.pone.0238283.t001
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Discussion
This study combined a postal survey with a pilot brain imaging analysis to help characterise
features of NCGS which may assist in future research trials, particularly those which may wish
to focus on neurological outcomes.
There is a need for diagnostic biomarkers of NCGS [13]. There is limited research showing
AGA is raised in NCGS patients compared to the general population [11]. In the current study
the positivity rate in patients was 17.9%, compared to 12.5% of healthy volunteers, (a non-sig-
nificant difference). This generally supports previous literature showing that it is not overall a
strong measure for diagnosing conventional NCGS [14]. Future research may still benefit
from investigation of how gliadin positivity may interact with neurological outcomes specifi-
cally, as these antibodies have been indicated as potentially harmful for the brain [24].
The brain has been shown to be affected in a number of gluten-related disorders, from
blunt neurological conditions like gluten ataxia [25] to “classical” CD [16, 17, 26, 27]. In the
current study neurological symptoms during typical gluten reactions of “classic” NCGS
patients were reported at high rates, including headaches and brain fog each in approximately
half of the group, as well as feeling off-balance in a third of subjects and sensory symptoms in a
fifth. Symptom severity was reported to increase markedly and by similar amounts when com-
paring intestinal and extra-intestinal outcomes; overall approximately four fifths of patients
felt at least 30% worse in one of these subtypes. This indicates they likely meet the Salerno cri-
teria [13] for inclusion in randomised trials.
Median time of symptom onset was reported as being 90 minutes; almost half of partici-
pants experienced symptoms within the first hour. Median symptom resolution time was 2
days, with just over three-quarters of patients recovering within a week. The pattern of onset
time was not significantly different to that in CD patients from the same centre. NCGS and
CD are known to be very similar in terms of their symptomatic presentation, and this draws
further attention to the high degree of overlap between the conditions. It also shows that it is
feasible for future studies to attempt physiological measurements of response to gluten chal-
lenges during the same study visits.
These findings, indicating overall that neurological features in NCGS may be very relevant
to the pathophysiology of the condition, motivated a pilot analysis to perform the first ever
brain imaging of NCGS patients. This was completed on five participants, and is presented as
a pilot study so that these methods may be introduced in this context. The purpose of pilot
studies are to “examine the feasibility of an approach that is intended to be used in a larger
scale study” [28], rather than being a full and formal analysis. Discussion presented here is
given with the purpose of introducing potential future neurological biomarkers for such
Table 2. Data pertaining to the gluten challenge portion of the pilot analysis. Symptom change scores are percentages derived from visual analogue scales administered
before and after the gluten, and a higher value always indicates a worse outcome; headache and brain fog both changed significantly across the group. CBF values are given
in units of ml/min/100g.
Subject Anxiety change Depression change Headache change Brain fog
change
Overall unwellness
change
Baseline GM
CBF
Follow-up GM
CBF
CBF % change
1� -3.1% -32.3% +17.7% +20.8% +17.7% 34.5 31.4 -8.9%
2 -15.6% +2.1% +1.0% +10.4% +9.4% 27.8 46.8 +68.4%
3 +4.2% +4.2% +19.8% +26.0% +30.2% 36.2 36.6 +1%
4 -57.3% -64.6% +34.4% +71.9% -12.5% 38.5 43.4 +12.8%
5 +2.1% +1.0% +36.5% +27.1% +27.1% 41.4 36.6 -11.6%
�All subjects except #1 completed both testing sessions on the same day; subject 1 completed baseline and gluten-challenge sessions 18 days apart.
https://doi.org/10.1371/journal.pone.0238283.t002
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studies, which may also seek to include control groups or other NCGS patient subgroups, and
is not a set of “formal” findings or interpretations.
In replications of routine clinical protocol, suspicious quantities of white matter lesions
(N = 3) and low vermis NAA/Cr ratios (N = 2) were reported. These were each investigated as
other research has indicated these may hold relevance to other gluten-related disorders. White
matter lesions are a non-specific brain pathology known to occur during normal aging [29]. How-
ever, they appear with greater size and frequency in a number of conditions such as vascular
dementia [30] and multiple sclerosis [31], and have also been reported as an outcome in CD [16]
(potentially linking with the increased risk of vascular dementia which CD is known to carry
[32]). Similarly, lowNAA/Cr is also known to be present in CD [17] and other neurological gluten
conditions such as gluten ataxia [33]. These values were found to fall below clinical cut-offs in two
of the current subjects and were therefore flagged as potentially abnormal. These cut-offs are the
same as used clinically, and are set as being two standard deviations below the mean values of
healthy controls, imaged with the same sequence on the same scanner as part of local calibrations.
Accompanying these imaging results, the Hospital Anxiety and Depression Scale also determined
one subject met full criteria for anxiety, and another to be “borderline” for both anxiety and
depression. Depression and anxiety have been shown to be comorbidities of CD [34].
The imaging study also involved an interventional component whereby participants completed
other assessments before and after a gluten challenge. Feelings of brain fog and headache each
worsened in a consistent pattern and by an overall significant magnitude after eating gluten,
although the lack of a placebo-controlled design means this should be interpreted with caution. A
repeat MRI scan also measured CBF. The method used to study this, “ASL”, is popular within
neuroimaging research [35, 36], but does suffer from relatively high levels of noise [37]. This is
important to consider as only very marked differences in CBF should be considered potentially
interesting. Four of the five subjects showed neither a “large” or consistent CBF change, however
for the final participant CBF increased by 69% after eating gluten. While this may hypothetically
represent a dynamic physiological response to the gluten challenge, a number of factors outside of
the control of the study design can influence CBF over the course of a day [38].
The study has a number of limitations. Patients who may be sensitive to causative agents
other than gluten, such as FODMAPs, were not directly controlled for. However, this possibility
will have been some part of the initial clinical investigations for the patients and therefore the like-
lihood of this should have been reduced by some degree. As already discussed, the imaging study
is also significantly limited by its small sample size, and aspects of its interventional component
are additionally confounded by the possibility of “nocebo” effects (although this should not influ-
ence the CBF readings, as they are physiological measurements). As stated, it is not appropriate to
consider this part of the paper a full, formal scientific analysis, and discussion around those find-
ings is only intended to indicate potentially interesting future research avenues.
Conclusions
A combined postal survey and brain imaging analysis revealed that “typical” NCGS frequently
involves neurological symptoms, of non-trivial severity, which may be studied within 2 hours fol-
lowing gluten ingestion. The first neuroimaging data of its kind characterised a number of clinical
variables which may be useful variables in future trials studying the pathophysiology of NCGS.
Supporting information
S1 File.
(SAV)
PLOS ONE Brain fog and non-coeliac gluten sensitivity
PLOS ONE | https://doi.org/10.1371/journal.pone.0238283 August 28, 2020 8 / 11
S2 File.
(DOCX)
Author Contributions
Conceptualization: Nigel Hoggard, Marios Hadjivassiliou, David S. Sanders.
Data curation: Iain D. Croall, Nigel Hoggard, Imran Aziz, Marios Hadjivassiliou, David S.
Sanders.
Formal analysis: Iain D. Croall, Nigel Hoggard.
Investigation: Nigel Hoggard, Imran Aziz, David S. Sanders.
Methodology: Iain D. Croall, Nigel Hoggard, David S. Sanders.
Project administration: Nigel Hoggard, David S. Sanders.
Supervision: Nigel Hoggard, Marios Hadjivassiliou, David S. Sanders.
Writing – original draft: Iain D. Croall.
Writing – review & editing: Nigel Hoggard, Imran Aziz, Marios Hadjivassiliou, David S.
Sanders.
References
1. Sapone A, Bai JC, Ciacci C, et al. Spectrum of gluten-related disorders: consensus on new nomencla-
ture and classification. BMC Med 2012; 10(1):13.
2. Aziz I, Lewis NR, Hadjivassiliou M, et al. A UK study assessing the population prevalence of self-
reported gluten sensitivity and referral characteristics to secondary care. Eur J Gastroenterol Hepatol
2014; 26(1):33–9. https://doi.org/10.1097/01.meg.0000435546.87251.f7 PMID: 24216570
3. Volta U, Bardella M, Calabrz A, Troncone R, Corazza G. An Italian prospective multicenter survey on
patients suspected of having non-celiac gluten sensitivity. BMC Med 2014; 12(85):1–8.
4. Jones AL. The Gluten-Free Diet: Fad or Necessity? Diabetes Spectr 2017; 30(2):118–23. https://doi.
org/10.2337/ds16-0022 PMID: 28588378
5. Croall ID, Trott N, Rej A, et al. A population survey of dietary attitudes towards Gluten. Nutrients 2019;
11(6):1–8.
6. Catassi C, Alaedini A, Bojarski C, et al. The overlapping area of non-celiac gluten sensitivity (NCGS)
and wheat-sensitive irritable bowel syndrome (IBS): An update. Nutrients 2017; 9(11):E1268. https://
doi.org/10.3390/nu9111268 PMID: 29160841
7. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in
patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly
absorbed, short-chain carbohydrates. Gastroenterology 2013; 145(2):320–328.e3. https://doi.org/10.
1053/j.gastro.2013.04.051 PMID: 23648697
8. Volta U, Tovoli F, Cicola R, et al. Serological tests in gluten sensitivity (nonceliac gluten intolerance). J
Clin Gastroenterol 2012; 46(8):680–5. https://doi.org/10.1097/MCG.0b013e3182372541 PMID:
22138844
9. Carroccio A, Mansueto P, Iacono G, et al. Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind
Placebo-Controlled Challenge: Exploring a New Clinical Entity. Am J Gastroenterol 2012; 107
(12):1898–906. https://doi.org/10.1038/ajg.2012.236 PMID: 22825366
10. Uhde M, Ajamian M, Caio G, et al. Intestinal cell damage and systemic immune activation in individuals
reporting sensitivity to wheat in the absence of coeliac disease. Gut 2016; 65(12):1930–7. https://doi.
org/10.1136/gutjnl-2016-311964 PMID: 27459152
11. Roszkowska A, Pawlicka M, Mroczek A, Bałabuszek K, Nieradko-Iwanicka B. Non-celiac gluten sensi-
tivity: A review. Med 2019; 55(6):1–19.
12. Lionetti E, Pulvirenti A, Vallorani M, et al. Re-challenge Studies in Non-celiac Gluten Sensitivity: A Sys-
tematic Review and Meta-Analysis. Front Physiol 2017; 8(September):1–9. https://doi.org/10.3389/
fphys.2017.00001
PLOS ONE Brain fog and non-coeliac gluten sensitivity
PLOS ONE | https://doi.org/10.1371/journal.pone.0238283 August 28, 2020 9 / 11
13. Catassi C, Elli L, Bonaz B, et al. Diagnosis of non-celiac gluten sensitivity (NCGS): The salerno experts’
criteria. Nutrients 2015; 7(6):4966–77. https://doi.org/10.3390/nu7064966 PMID: 26096570
14. Infantino M, Manfredi M, Meacci F, et al. Diagnostic accuracy of anti-gliadin antibodies in Non Celiac
Gluten Sensitivity (NCGS) patients: A dual statistical approach. Clin Chim Acta [Internet] 2015;
451:135–41. https://doi.org/10.1016/j.cca.2015.09.017 PMID: 26404177
15. Currie S, Hadjivassiliou M, Clark MJ, et al. Should we be “nervous” about coeliac disease? Brain abnor-
malities in patients with coeliac disease referred for neurological opinion. J Neurol Neurosurg Psychiatry
2012; 83(12):1216–21. https://doi.org/10.1136/jnnp-2012-303281 PMID: 22906616
16. Hadjivassiliou M, Croall ID, Zis P, et al. Neurologic Deficits in Patients With Newly Diagnosed Celiac
Disease Are Frequent and Linked With Autoimmunity to Transglutaminase 6. Clin Gastroenterol Hepa-
tol 2019; 17(13):2678–86. https://doi.org/10.1016/j.cgh.2019.03.014 PMID: 30885888
17. Addolorato G, Di Giuda D, De Rossi G, et al. Regional cerebral hypoperfusion in patients with celiac dis-
ease. Am J Med 2004; 116(5):312–7. https://doi.org/10.1016/j.amjmed.2003.09.037 PMID: 14984816
18. Carroccio A, Giambalvo O, La Blasca F, Iacobucci R, D’Alcamo A, Mansueto P. Self-reported non-
celiac wheat sensitivity in high school students: Demographic and clinical characteristics. Nutrients
2017; 9(7):1–9.
19. Silvester JA, Graff LA, Rigaux L, Walker JR, Duerksen DR. Symptomatic suspected gluten exposure is
common among patients with coeliac disease on a gluten-free diet. Aliment Pharmacol Ther 2016; 44
(6):612–9. https://doi.org/10.1111/apt.13725 PMID: 27443825
20. Hadjivassiliou M, Gru¨newald RA, Sanders DS, et al. The Significance of Low Titre Antigliadin Antibodies
in the Diagnosis of Gluten Ataxia. Nutrients 2018; 10(10):1444.
21. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67
(6):361–70. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x PMID: 6880820
22. Leffler D., Schuppan D., Pallav K., Najarian R., Goldsmith J. D., Hansen J., et al. (2013). Kinetics of the
histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease.
Gut, 62(7), 996–1004. https://doi.org/10.1136/gutjnl-2012-302196 PMID: 22619366
23. Barratt SM, Leeds JS, Sanders DS. Factors influencing the type, timing and severity of symptomatic
responses to dietary gluten in patients with biopsy-proven coeliac disease. J Gastrointest Liver Dis
2013; 22(4):391–6.
24. Pratesi R, Gandolfi L, Friedman H, Farage L, de Castro CA, Catassi C. Serum IgA antibodies from
patients with coeliac disease react strongly with human brain blood-vessel structures. Scand J Gastro-
enterol. 1998; 33(8):817–821. https://doi.org/10.1080/00365529850171468 PMID: 9754728
25. Hadjivassiliou M, Sanders DS, Woodroofe N, Williamson C, Gru¨newald RA. Gluten ataxia. Cerebellum
2008; 7(3):494–8. https://doi.org/10.1007/s12311-008-0052-x PMID: 18787912
26. Casella S, Zanini B, Lanzarotto F, et al. Cognitive performance is impaired in coeliac patients on gluten
free diet: A case-control study in patients older than 65 years of age. Dig Liver Dis 2012; 44(9):729–35.
https://doi.org/10.1016/j.dld.2012.03.008 PMID: 22484003
27. Lichtwark IT, Newnham ED, Robinson SR, et al. Cognitive impairment in coeliac disease improves on a
gluten-free diet and correlates with histological and serological indices of disease severity. Aliment
Pharmacol Ther 2014; 40(2):160–70. https://doi.org/10.1111/apt.12809 PMID: 24889390
28. Leon A.C., Davis L.L., & Kraemer H.C. (2010). The Role and Interpretation of Pilot Studies in Clinical
Research, Journal of Psychiatric Research, 45(5), 626–629. https://doi.org/10.1016/j.jpsychires.2010.
10.008 PMID: 21035130
29. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic reso-
nance imaging: Systematic review and meta-analysis. BMJ 2010; 341(7767):288.
30. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel dis-
ease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12(8):822–38. https://
doi.org/10.1016/S1474-4422(13)70124-8 PMID: 23867200
31. Papadopoulou A, Mu¨ller-Lenke N, Naegelin Y, et al. Contribution of cortical and white matter lesions to
cognitive impairment in multiple sclerosis. Mult Scler J 2013; 19(10):1290–6.
32. Lebwohl B, Luchsinger JA, Freedberg DE, Green PHR, Ludvigsson JF. Risk of Dementia in Patients
with Celiac Disease: A Population-Based Cohort Study. J Alzheimer’s Dis 2016; 49(1):179–85.
33. Hadjivassiliou M, Grunewald RA, Sanders DS, Shanmugarajah P, Hoggard N. Effect of gluten-free diet
on cerebellar MR spectroscopy in gluten ataxia. Neurology 2017;
34. Zingone F, Swift GL, Card TR, Sanders DS, Ludvigsson JF, Bai JC. Psychological morbidity of celiac
disease: A review of the literature. United Eur Gastroenterol J 2015; 3(2):136–45.
35. Alsop DC, Detre JA, Golay X, et al. Recommended implementation of arterial spin-labeled Perfusion
mri for clinical applications: A consensus of the ISMRM Perfusion Study group and the European
PLOS ONE Brain fog and non-coeliac gluten sensitivity
PLOS ONE | https://doi.org/10.1371/journal.pone.0238283 August 28, 2020 10 / 11
consortium for ASL in dementia. Magn Reson Med 2015; 73(1):102–16. https://doi.org/10.1002/mrm.
25197 PMID: 24715426
36. Wolk DA, Detre JA. Arterial spin labeling MRI: An emerging biomarker for Alzheimer’s disease and
other neurodegenerative conditions. Curr Opin Neurol 2012; 25(4):421–8. https://doi.org/10.1097/
WCO.0b013e328354ff0a PMID: 22610458
37. Wu B, Lou X, Wu X, Ma L. Intra- and interscanner reliability and reproducibility of 3D whole-brain
pseudo-continuous arterial spin-labeling MR perfusion at 3T. J Magn Reson Imaging 2014; 39(2):402–
9. https://doi.org/10.1002/jmri.24175 PMID: 23723043
38. Joris P. J., Mensink R. P., Adam T. C., & Liu T. T. (2018). Cerebral Blood Flow Measurements in Adults:
A Review on the Effects of Dietary Factors and Exercise. Nutrients, 10(5), 530.
PLOS ONE Brain fog and non-coeliac gluten sensitivity
PLOS ONE | https://doi.org/10.1371/journal.pone.0238283 August 28, 2020 11 / 11
